Back to Journals » Patient Preference and Adherence » Volume 13

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide

Authors Ridolo E, Pellicelli I, Gritti B, Incorvaia C

Received 17 October 2018

Accepted for publication 20 December 2018

Published 14 January 2019 Volume 2019:13 Pages 145—150


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen

Erminia Ridolo,1 Irene Pellicelli,1 Bruna Gritti,2 Cristoforo Incorvaia2

1Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy; 2Cardiac/Pulmonary Rehabilitation Unit, ASST Pini-CTO, Milan, Italy

Abstract: Dual bronchodilation with long-acting beta-2 agonists and muscarinic antagonists is recommended in patients with severe to very severe COPD. Among dual bronchodilator combinations, indacaterol/glycopyrronium combination (IGC) received evidence of higher efficacy and good safety compared with monotherapy with either drug as well as with tiotropium. In randomized controlled trials, the primary outcome is usually the change in mean FEV1 resulting from treatment. However, the functional aspects that influence the physician’s choice of the type of management may not be considered important by the patient, based on his perception of the disease. To address such issue, patient-reported outcomes (PROs) were assessed in recent studies. They include patient’s perception of breathlessness, physical functioning, global health status, quality of life, use of rescue medications, and patient’s report of COPD exacerbations. PRO data from the studies showed a clear improvement in patients’ awareness of a better control of the disease in patients treated with IGC. In addition, the latest literature on two important issues influencing patient’s preference and adherence, ie, the once-daily administration and the device to be used, confirmed the effectiveness of IGC and the ability of its device (Breezhaler®) to result in patient’s satisfaction, ease of use, less handling errors, and self-assurance to have inhaled the entire dose.

severe COPD, dual bronchodilation, long-acting beta-2 agonists, long-acting muscarinic antagonists, efficacy, patient’s perception

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]